Ovid Therapeutics (NASDAQ:OVID) Posts Quarterly Earnings Results, Beats Estimates By $0.16 EPS

Ovid Therapeutics (NASDAQ:OVID) posted its quarterly earnings data on Wednesday. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.16, FiscalAI reports. Ovid Therapeutics had a negative net margin of 550.04% and a negative return on equity of 63.79%. The company had revenue of $0.72 million for the quarter, compared to the consensus estimate of $0.06 million.

Here are the key takeaways from Ovid Therapeutics’ conference call:

• Regulatory clearance for the oral KCC2 activator OV4071 (Australia) plus a $60M PIPE and a 30‑day Series A warrant window that could add >$53M — management says this combination gives a pro forma cash runway well into 2029.
• The 7 mg dose of OV329 showed no treatment‑related serious adverse events, no ophthalmic safety signals, and linear PK in healthy volunteers, which management says materially de‑risks the program and supports two doses for Phase II.
• Ovid is expanding OV329 into pediatric/rare indications, initiating signal‑finding and safety studies in infantile spasms and tuberous sclerosis complex (TSC) with plans for weight‑based pediatric formulations and potential efficient combined pivotal pathways.
• Multiple near‑term clinical catalysts are planned — a randomized Phase II FOS trial starting Q2 2026, an open‑label photosensitivity study later in 2026, a Phase I for OV4071 and a ketamine challenge this year — with several readouts expected through 2027.

Ovid Therapeutics Stock Performance

Shares of NASDAQ:OVID traded up $0.01 on Thursday, hitting $2.31. The company had a trading volume of 2,154,908 shares, compared to its average volume of 2,359,580. Ovid Therapeutics has a 1-year low of $0.24 and a 1-year high of $2.50. The stock has a market cap of $164.14 million, a price-to-earnings ratio of -4.61 and a beta of 0.25. The stock has a 50 day moving average price of $1.67 and a 200 day moving average price of $1.56. The company has a current ratio of 4.24, a quick ratio of 4.24 and a debt-to-equity ratio of 0.28.

Analyst Ratings Changes

Several analysts have issued reports on OVID shares. Lifesci Capital initiated coverage on shares of Ovid Therapeutics in a research report on Monday, December 22nd. They set an “outperform” rating and a $4.00 price target on the stock. Wall Street Zen lowered shares of Ovid Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ovid Therapeutics in a report on Thursday, January 22nd. Roth Mkm assumed coverage on shares of Ovid Therapeutics in a research note on Thursday, December 11th. They issued a “buy” rating and a $3.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $2.00 price target on shares of Ovid Therapeutics in a report on Monday, December 22nd. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Ovid Therapeutics has a consensus rating of “Buy” and an average target price of $4.00.

Institutional Trading of Ovid Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Invesco Ltd. bought a new position in Ovid Therapeutics during the 4th quarter worth $54,000. ADAR1 Capital Management LLC boosted its position in shares of Ovid Therapeutics by 33,256.7% during the 4th quarter. ADAR1 Capital Management LLC now owns 4,285,000 shares of the company’s stock worth $6,985,000 after acquiring an additional 4,272,154 shares in the last quarter. Quadrature Capital Ltd boosted its position in shares of Ovid Therapeutics by 217.2% during the 4th quarter. Quadrature Capital Ltd now owns 87,874 shares of the company’s stock worth $143,000 after acquiring an additional 60,171 shares in the last quarter. Millennium Management LLC increased its stake in shares of Ovid Therapeutics by 35.8% in the 4th quarter. Millennium Management LLC now owns 1,339,465 shares of the company’s stock valued at $2,183,000 after purchasing an additional 353,172 shares during the last quarter. Finally, Ally Bridge Group NY LLC bought a new stake in shares of Ovid Therapeutics during the 4th quarter worth $2,910,000. Institutional investors and hedge funds own 72.24% of the company’s stock.

Ovid Therapeutics News Roundup

Here are the key news stories impacting Ovid Therapeutics this week:

• Positive Sentiment: 7 mg OV329 Phase 1 cohort showed favorable safety/tolerability with no treatment‑related SAEs and supportive PK/biomarker data (builds on 3 mg/5 mg cortical inhibition signals); company plans Phase 2 patient studies in focal onset seizures. Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: OV4071 (oral KCC2 activator) received HREC/TGA acknowledgment to enter Phase 1 in Australia — expands pipeline beyond GABA‑AT approach and creates near‑term clinical milestones. Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Ovid priced a $60M private placement (PIPE) led by Point72 to fund OV329 expansion into tuberous sclerosis complex (TSC) and infantile spasms (IS) and general R&D — provides runway and shows institutional backing. Ovid Therapeutics Secures $60 Million in PIPE Financing to Advance OV329 Development for Tuberous Sclerosis Complex and Infantile Spasms
• Positive Sentiment: Q4 results beat estimates — GAAP net income in the quarter (driven by a fair‑value gain) and EPS above consensus; revenue and cash position improved (cash, cash equivalents and marketable securities ~$90.4M) supporting near‑term programs. Ovid Therapeutics Shares Rise After Swinging to 4Q Profit, Expanding Treatment
• Neutral Sentiment: Management outlined an accelerated milestone cadence (Phase 2 start for OV329 expected Q2 2026; open‑label and other proof‑of‑concept studies planned; KCC2 R&D day April 14) — these create multiple binary catalysts but also timing risk. Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: PIPE involves issuance of ~19.15M shares and pre‑funded warrants (priced at $2.01) — meaningful near‑term dilution risk for existing holders; warrant exercise dynamics could further alter share count. Ovid Therapeutics Secures $60 Million in PIPE Financing to Advance OV329 Development for Tuberous Sclerosis Complex and Infantile Spasms
• Negative Sentiment: Company remains unprofitable for the year (2025 net loss ~$17.4M) with high operating expenses versus limited commercial revenue — clinical failures or delays would hurt valuation. Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates

Ovid Therapeutics Company Profile

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.